Bortezomib: a proteasome inhibitor for the treatment of autoimmune diseases.

Khalesi, Naeemeh; Korani, Shahla; Korani, Mitra; Johnston, Thomas P; Sahebkar, Amirhossein

Khalesi, Naeemeh; Korani, Shahla; Korani, Mitra; Johnston, Thomas P; Sahebkar, Amirhossein.

Afiliación

Khalesi N; Biotechnology Department, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Science, Tehran, Iran.
Korani S; Research Center of Oils and Fats, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Korani M; Nanotechnology Research Center, Buali (Avicenna) Research Center, Mashhad University of Medical Science, Mashhad, Iran.
Johnston TP; Division of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, Kansas City, MO, 64108, USA.
Sahebkar A; Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. sahebkara@mums.ac.ir.

Inflammopharmacology ; 29(5): 1291-1306, 2021 Oct.

Article en En | MEDLINE | ID: mdl-34424482

Asunto(s)

Enfermedades Autoinmunes/tratamiento farmacológico; Bortezomib/farmacología; Inhibidores de Proteasoma/farmacología; Animales; Antineoplásicos/farmacología; Enfermedades Autoinmunes/fisiopatología; Modelos Animales de Enfermedad; Resistencia a Medicamentos; Humanos; Mieloma Múltiple/tratamiento farmacológico

Palabras clave

Autoimmune disease; Bortezomib; ER homeostasis; NF-kB; Proteasome; Proteasome inhibitor

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Enfermedades Autoinmunes / Inhibidores de Proteasoma / Bortezomib Límite: Animals / Humans Idioma: En Revista: Inflammopharmacology Asunto de la revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2021 Tipo del documento: Article País de afiliación: Irán

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google